A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Last updated: February 15, 2025
Sponsor: Yizhuo Zhang
Overall Status: Active - Recruiting

Phase

3

Condition

Rhabdomyosarcoma

Neuroblastoma

Retinoblastoma

Treatment

VAC，VAC/VII，CAV/IE

Clinical Study ID

NCT06836492
SYSUCC-RMS
  • Ages < 18
  • All Genders

Study Summary

The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 0 years < age < 18 years old, regardless of gender;

  2. Tumor patients diagnosed by histopathology or bone marrow cytology;

  3. Patients are treated for the first time;

  4. ECoG score ≤ 2;

  5. The expected survival time is more than 8 months;

  6. Patient's parent or guardian signs informed consent.

Exclusion

Exclusion Criteria:

  1. Combined with immunodeficiency disease

  2. Second tumor

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: VAC，VAC/VII，CAV/IE
Phase: 3
Study Start date:
January 30, 2017
Estimated Completion Date:
December 31, 2029

Connect with a study center

  • Suying Lu

    Guangzhou, Guangdong 510060
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.